Leisure Sitting Time Linked to Increased Risk of Malignancies in Women

Share this content:

the Cancer Therapy Advisor take:

Women with longer amounts of leisure-time spent sitting have a greater risk of total cancer, while no correlation was found between sitting time and men, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

Participants in this study included individuals who were initially cancer-free and enrolled in the American Cancer Society Cancer Prevention Study II Nutrition Cohort (from 1992 to 2009).  Of 69,260 men, 18,555 were diagnosed with cancer, compared to 12,236 women diagnosed out of 77,462.

The authors adjusted the data for physical activity, BMI, and other factors—noting that physical activity was independent of sitting time.

Results showed that longer sitting time was associated with malignancy in women (relative risks (RR) = 1.10; 95% CI: 1.04, 1.17 for >6 hours vs. <3 hours/day), but not in men (RR=1.00; 95% CI: 0.96, 1.05).

Women with greater levels of leisure-time spent sitting were at greater risk for developing site-specific cancers such as multiple myeloma (RR=1.65; 95% CI: 1.07, 2.54), invasive breast cancer (RR=1.10; 95% CI: 1.00, 1.21), and ovarian cancer (RR=1.43; 95% CI: 1.10, 1.87).

The study suggests further research be conducted regarding the different correlations between men and women. Furthermore, it supports the American Cancer Society’s recommendation to reduce leisure-time spent sitting whenever possible.

Leisure Sitting Time Linked to Increased Risk of Malignancies in Women
Women with longer amounts of leisure-time spent sitting have a greater risk of total cancer.
Time spent sitting is distinctly different from accumulating too little physical activity and may have independent deleterious effects.
READ FULL ARTICLE From cebp.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters